Practical strategies to normalize hyperglycemia without undue hypoglycemia in type 2 diabetes mellitus

Current Diabetes Reports

Volumn 8, Issue 5, 2008, Pages 375-382

  Kodl, Christopher T ^b   Seaquist, Elizabeth R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AMYLIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; ANTIDIABETIC AGENT;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; BRADYCARDIA; CARBOHYDRATE INTAKE; CELL FUNCTION; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT EDUCATION; POPULATION RISK; QT PROLONGATION; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; ST SEGMENT DEPRESSION; T WAVE; TACHYCARDIA; UPREGULATION; ARTICLE; BLOOD; RISK ASSESSMENT;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; RISK ASSESSMENT; RISK FACTORS;

EID: 58149390114     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0065-3     Document Type: Review

References (71)

1. American Diabetes Association: Standards of medical care in diabetes - 2007. Diabetes Care 2007, 30(Suppl 1):S4-S41.
2. Lindstrom T, Jorfeldt L, Tegler L, et al.: Hypoglycaemia and cardiac arrhythmias in patients with type 2 diabetes mellitus. Diabet Med 1992, 9:536-541.
3. Landstedt-Hallin L, Englund A, Adamson U, et al.: Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999, 246:299-307.
4. Desouza C, Salazar H, Cheong B, et al.: Association of hypoglycemia and cardiac ischemia: A study based on continuous monitoring. Diabetes Care 2003, 26:1485-1489.
5. Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
6. Stork AD, van HaDften TW, Veneman TF: Diabetes and driving: desired data, research methods and their pitfalls, current knowledge, and future research. Diabetes Care 2006, 29:1942-1949.
7. Chico A, Vidal-Rios P, Subira M, et al.: The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003, 26:1153-1157.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837-853.
9. Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
10. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
11. Banarer S, Cryer PE: Hypoglycemia in type 2 diabetes. Med Clin North Am 2004, 88:1107-1116, xii-xiii.
12. Criego A, Kumar A, Tran N, et al.: Brain glucose concentrations in patients with type 1 diabetes and hypoglycemia unawareness. J Neurosci Res 2005, 79:42-47.
13. Choi IY, Seaquist ER, Gruetter R: Effect of hypoglycemia on brain glycogen metabolism in vivo. J Neurosci Res 2003, 72:25-32.
14. Israelian Z, Szoke E, Woerle J, et al.: Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus. Metabolism 2006, 55:593-598.
15. Segel SA, Paramore DS, Cryer PE: Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002, 51:724-733.
16. Davis MR, Mellman M, Shamoon H: Further defects in counterregulatory responses induced by recurrent hypoglycemia in IDDM. Diabetes 1992, 41:1335-1340.
17. Bolli GB, Tsalikian E, Haymond MW, et al.: Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest 1984, 73:1532-1541.
18. Henderson JN, Allen KV, Deary IJ, et al.: Hypoglycaemia in insulin-treated type 2 diabetes: Frequency, symptoms and impaired awareness. Diabet Med 2003, 20:1016-1021.
19. Levitt NS, Vinik AI, Sive AA, et al.: Studies on plasma glucagon concentration in maturity-onset diabetics with autonomic neuropathy. Diabetes 1979, 28:1015-1021.
20. Miller CD, Phillips LS, Ziemer DC, et al.: Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001, 161:1653-1659.
21. McGregor VP, Greiwe JS, Banarer S, et al.: Limited impact of vigorous exercise on defenses against hypoglycemia: Relevance to hypoglycemia-associated autonomic failure. Diabetes 2002, 51:1485-1492.
22. Rattarasarn C, Dagogo-Jack S, Zachwieja JJ, et al.: Hypoglycemia-induced autonomic failure in IDDM is specific for stimulus of hypoglycemia and is not attributable to prior autonomic activation. Diabetes 1994, 43:809-818.
23. Minuk HL, Vranic M, Marliss EB, et al.: Glucoregulatory and metabolic response to exercise in obese noninsulin-dependent diabetes. Am J Physiol 1981, 240:E458-E464.
24. Chipkin SR, Klugh SA, Chasan-Taber L: Exercise and diabetes. Cardiol Clin 2001, 19:489-505.
25. Jones TW, Porter P, Sherwin RS, et al.: Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998, 338:1657-1662.
26. Brierley EJ, Broughton DL, James OF, et al.: Reduced awareness of hypoglycaemia in the elderly despite an intact counter-regulatory response. QJM 1995, 88:439-445.
27. Meneilly GS, Cheung E, Tuokko H: Altered responses to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 1994, 78:1341-1348.
28. Fink RI, Revers RR, Kolterman OG, et al.: The metabolic clearance of insulin and the feedback inhibition of insulin secretion are altered with aging. Diabetes 1985, 34:275-280.
29. Seltzer HS: Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am 1989, 18:163-183.
30. ter Braak EW, Appelman AM, van de Laak M, et al.: Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 2000, 23:1467-1471.
31. Cryer PE: Severe iatrogenic hypoglycemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2007, 3:4-5.
32. Avogaro A, Beltramello P, Gnudi L, et al.: Alcohol intake impairs glucose counterregulation during acute insulin-induced hypoglycemia in IDDM patients. Evidence for a critical role of free fatty acids. Diabetes 1993, 42:1626-1634.
33. Rasmussen BM, Orskov L, Schmitz O, et al.: Alcohol and glucose counterregulation during acute insulin-induced hypoglycemia in type 2 diabetic subjects. Metabolism 2001, 50:451-457.
34. Hartling SG, Faber OK, Wegmann ML, et al.: Interaction of ethanol and glipizide in humans. Diabetes Care 1987, 10:683-686.
35. Hirai FE, Moss SE, Klein BE, et al.: Severe hypoglycemia and smoking in a long-term type 1 diabetic population: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 2007, 30:1437-1441.
36. Bott S, Shafagoj YA, Sawicki PT, et al.: Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. Horm Metab Res 2005, 37:445-449.
37. Porcellati F, Rossetti P, Busciantella NR, et al.: Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study. Diabetes Care 2007, 30:2447-2452.
38. Rosenstock J, Dailey G, Massi-Benedetti M, et al.: Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005, 28:950-955.
39. Raskin P, Allen E, Hollander P, et al.: Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28:260-265.
40. Rossetti P, Porcellati F, Ricci NB, et al.: Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. Diabetes 2008, 57:746-756.
41. Philis-Tsimikas A, Charpentier G, Clauson P, et al.: Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006, 28:1569-1581.
42. Pieber TR, Treichel HC, Hompesch B, et al.: Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007, 24:635-642.
43. Wang XL, Lu JM, Pan CY, et al.: Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. Diabetes Res Clin Pract 2007, 76:30-36.
44. Plank J, Siebenhofer A, Berghold A, et al.: Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005, 165:1337-1344.
45. Herman WH, Ilag LL, Johnson SL, et al.: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005, 28:1568-1573.
46. Draeger KE, Wernicke-Panten K, Lomp HJ, et al.: Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): A double-blind comparison with glibenclamide. Horm Metab Res 1996, 28:419-425.
47. Asplund K, Wiholm BE, Lithner F: Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983, 24:412-417.
48. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854-865.
49. Hollander P, Yu D, Chou HS: Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes. Arch Intern Med 2007, 167:1284-1290.
50. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
51. Johnston PS, Lebovitz HE, Coniff RF, et al.: Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998, 83:1515-1522.
52. Nattrass M, Lauritzen T: Review of prandial glucose regulation with repaglinide: A solution to the problem of hypoglycaemia in the treatment of type 2 diabetes? Int J Obes Relat Metab Disord 2000, 24(Suppl 3):S21-S31.
53. Vilsboll T, Krarup T, Madsbad S, et al.: No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med 2001, 18:144-149.
54. Davis SN, Johns D, Maggs D, et al.: Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007, 30:2767-2772.
55. Raz I, Hanefeld M, Xu L, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571.
56. Goldstein BJ, Feinglos MN, Lunceford JK, et al.: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987.
57. Hermansen K, Kipnes M, Luo E, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:733-745.
58. Riddle M, Frias J, Zhang B, et al.: Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007, 30:2794-2799.
59. Nauck MA, Heimesaat MM, Behle K, et al.: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87:1239-1246.
60. Degn KB, Brock B, Juhl CB, et al.: Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397-2403.
61. Fonseca V, Schweizer A, Albrecht D, et al.: Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
62. Fleseriu M, Skugor M, Chinnappa P, et al.: Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide. Endocr Pract 2006, 12:635-640.
63. Murata GH, Hoffman RM, Shah JH, et al.: A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus: The Diabetes Outcomes in Veterans Study (DOVES). Arch Intern Med 2004, 164:1445-1450.
64. Kovatchev BP, Clarke WL: Continuous Glucose Monitoring (CGM) Reduces Risks for Hypo-and Hyperglycemia and Glucose Variability in Diabetes. Presented at the 67th Annual Diabetes Association Scientific Session. Chicago, IL; June 22-26, 2007.
65. Kesavadev J, Rasheed SA: Gatifloxacin induced abnormalities in glucose homeostasis in a patient on glimepiride. J Assoc Physicians India 2006, 54:951-952.
66. Friedrich LV, Dougherty R: Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004, 24:1807-1812.
67. Reynolds RM, Walker JD: Hypoglycaemia induced by disopyramide in a patient with type 2 diabetes mellitus. Diabet Med 2001, 18:1009-1010.
68. Klein J, Ott V, Schutt M, et al.: Recurrent hypoglycaemic episodes in a patient with type 2 diabetes under fibrate therapy. J Diabetes Complications 2002, 16:246-248.
69. Abraira C, Duckworth WC: Intense blood glucose control yields no significant effect on CVD reduction in VA Diabetes Trial. Presented at the American Diabetes Association 68th Annual Scientific Session. San Francisco, CA; June 6-10, 2008.
70. Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
71. Gaede P, Lund-Andersen H, Parving HH, et al.: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.